Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

February 14th 2022

Patrick Neven MD, PhD; Sara A. Hurvitz, MD; Kevin Kalinsky, MD, MS; and Aditya Bardia, MD, MPH, share insight on updates in key clinical trials and novel therapies in breast cancer presented at SABCS 2021.

Addition of Dalpiciclib to Fulvestrant Improves PFS in HR+ Advanced Breast Cancer

February 14th 2022

The addition of dalpiciclib to fulvestrant significantly prolonged progression-free survival vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to data from an interim analysis of the phase 3 DAWNA-1 trial.

Earlier Introduction of ADCs, PARP and CDK4/6 Inhibitors Improve Outcomes in Breast Cancer

February 13th 2022

Joanne Mortimer, MD, discusses current applications for HER2-directed antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors in early-stage and metastatic breast cancer.

Advances Improve Outcomes but Leave Space for Curative Strategies in Metastatic Breast Cancer

February 11th 2022

John T. Cole, MD, discusses how updates in HER2-positive breast cancer have affected sequencing strategies, selecting between CDK4/6 inhibitors in the adjuvant and metastatic settings of hormone receptor HR–positive breast cancer, and the need for additional therapies in triple-negative breast cancer.

Novel Treatment Approaches to R/R HER2+ Metastatic Breast Cancer

February 9th 2022

Experts discuss the role of novel therapies in relapsed/refractory HER2+ metastatic breast cancer accounting for results from recent clinical trial.

HER2+ mBC: Impact of T-DM1 and T-DXd Beyond the Frontline Setting

February 9th 2022

Shared insight on the roles of trastuzumab emtansine and trastuzumab deruxtecan in relapsed/refractory HER2+ metastatic breast cancer.

ctDNA in Breast Cancer: Cancer Detection Vs Therapy Selection

February 9th 2022

A brief synopsis on the use of circulating tumor DNA for cancer detection versus treatment selection in breast cancer management.

Role of ctDNA in the Adjuvant Setting of Breast Cancer

February 9th 2022

Aditya Bardia, MD, MPH, and Barry Rosen, MD, discuss the role of circulating tumor DNA in the adjuvant setting of breast cancer.

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

February 7th 2022

Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.

2021 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2022

In 2021, 13 novel agents were approved across hematology/oncology. Additionally, there were many other notable approvals—whether they were new formulations, expanded indications, or biosimilar approvals—across tumor types that expanded accessibility for varying patient populations.

Monitoring Patients With HER2+ Metastatic Breast Cancer

February 2nd 2022

A brief review of patient monitoring and screening practices in the setting of HER2+ metastatic breast cancer.

Patient Case: Frontline Treatment Options for HER2+ mBC

February 2nd 2022

Taking into account a patient case of HER2+ metastatic breast cancer, experts review current frontline treatment options.

Giants of Cancer Care Award in Breast Cancer Goes to Nancy E. Davidson, MD: The Introvert in the Front Row

February 1st 2022

A subtle superstar, Nancy E. Davidson, MD, is as adept at conducting groundbreaking research as she is at treating patients and corralling investigators.

Role of ctDNA in the Neoadjuvant Setting of Breast Cancer

February 1st 2022

Expert perspectives on the value of circulating tumor DNA in the neoadjuvant setting of breast cancer management.

Applications of ctDNA Assessment in Metastatic Breast Cancer and Relapse

February 1st 2022

Aditya Bardia, MD, MPH, shares insight on how circulating tumor DNA is used in metastatic breast cancer and relapse detection.

SABCS 2021 Updates in ER+ Breast Cancer

January 31st 2022

Experts in the management of breast cancer review recent data on SERDs (selective estrogen receptor degraders) in ER+/HER2 advanced breast cancer presented at SABCS [San Antonio Breast Cancer Symposium] 2021.

Making Progress Against the Blood-Brain Barrier

January 31st 2022

Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier, a highly restrictive interface between the bloodstream and the brain that prevents most drugs from accessing the brain parenchyma.

Patient Case: Biomarker Testing in Breast Cancer

January 26th 2022

Centered on a patient presentation of breast cancer, panelists consider optimal biomarker testing strategies to inform their treatment approach.

An Overview on the Current State of Metastatic Breast Cancer

January 26th 2022

Expert perspectives on the current treatment landscape of metastatic breast cancer and the unmet needs prevalent across various subsets of disease.

Targeted Therapy Innovator Foresees New Paradigms in Breast Cancer

January 26th 2022

Debu Tripathy, MD, discusses key developments that may set the stage for new directions in care of breast cancer, including several areas of the treatment landscape on the cusp of change.